ALIS (Amikacin Liposome Inhalation Suspension): The Beginning of a Wonderland?

Charles L Daley^{1

2}, Kenneth N Olivier³

Affiliations

Editorial

Charles L Daley et al. Am J Respir Crit Care Med. 2018.

. 2018 Dec 15;198(12):1473-1475.

doi: 10.1164/rccm.201810-1901ED.

Charles L Daley^{1

2}, Kenneth N Olivier³

No abstract available

Comment on

Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study.
Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, Addrizzo-Harris DJ, O'Donnell AE, Marras TK, Flume PA, Loebinger MR, Morgan L, Codecasa LR, Hill AT, Ruoss SJ, Yim JJ, Ringshausen FC, Field SK, Philley JV, Wallace RJ Jr, van Ingen J, Coulter C, Nezamis J, Winthrop KL; CONVERT Study Group. Griffith DE, et al. Am J Respir Crit Care Med. 2018 Dec 15;198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC. Am J Respir Crit Care Med. 2018. PMID: 30216086 Clinical Trial.

1. Wolinsky E. Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis. 1979;119:107–159. - PubMed
1. Branch A. A study of acid-fast organisms other than mammalian tubercle bacilli isolated from disease in man: the occurrence of avian tubercle bacillus infection of men and the diagnosis of avirulent avian tubercle bacilli. Tubercle. 1933;14:337–353.
1. Feldman WH, Davies R, Moses HE, Andberg W. An unusual mycobacterium. Am Rev Tuberc. 1943;48:82–93.
1. Cheung OT, Konst H. Pulmonary tuberculosis apparently caused by the avian tubercle bacillus. Can Med Assoc J. 1963;89:116–120. - PMC - PubMed
1. Rich AR.The pathogenesis of tuberculosis.Springfield, IL: Charles C. Thomas; 1944